Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Cell surface markers are used to identify and classify different cells. These markers play a vital role in immunology. The analysis of cell surface markers through immunophenotyping allows efficient disease identification, sample preparation, drug discovery, disease diagnosis and subsequent treatment determination.
The global cell surface markers market is estimated to account for US$ 24,961.0 Mn in terms of value in 2020 and is expected to reach US$ 44,373.4 Mn by the end of 2027.
Global Cell Surface Markers Market: Drivers
Growing automation in laboratories is expected to propel growth of the global cell surface markers market over the forecast period. Huge inflow of data pertaining to patient details, clinical information, type of test, and the instruments required demands streamlining of such processes. Rapid detection of critical medical conditions can be easily facilitated through the use of sophisticated laboratory equipment such as flow cytometers. Availability of high-end and faster cell sorting and analysis solutions in flow cytometers for research and clinical development facilitates easier use of point of care diagnosis through automation of sample processing and enabling high throughput screening.
Moreover, increasing adoption of in vitro diagnostics is also expected to aid in growth of the market. The in vitro diagnostics (IVD) includes diagnostic test products, instruments and consumables. IVD focuses on easy and rapid identification of disease conditions outside the body. Rapid incidence rate of chronic conditions such as cancer and cardiovascular diseases and the increased urgency to reduce disease diagnosis lead time has resulted in an increased demand for IVD. Cell marker analysis through sophisticated flow cytometers and advanced high-quality antibodies facilitate rapid disease diagnosis and efficient drug discovery.
North America held dominant position in the global cell surface markers market in 2019, accounting for 37.5% share in terms of value, followed by Europe and Asia Pacific, respectively
Figure 1. Global Cell Surface Markers Market Share (%), by Value, by Region, 2019
Global Cell Surface Markers Market: Restraints
Reluctance in high investment in sophisticated models is expected to hinder growth of the market. Due to the complexity and high cost of instruments and the simultaneous uncertainty surrounding the regulation and reimbursement for cell marker diagnostic tests, many clinical laboratories are reluctant to invest in sophisticated cell marker analysis instruments. Need for such devices also depends on the size and nature of the diagnostic facility. Economic concerns regarding operational sustainability in medium and small sized clinical laboratories and hospitals results in the outsourcing of such tasks to larger clinical laboratories.
Moreover, small pharmaceutical companies also are becoming increasingly reluctant to invest in highly sophisticated flow cytometers and hematology analyzers, owing to the unclear cost-benefit relationship. As drug development itself is a costly affair, smaller pharmaceutical firms cannot afford to get involved in the purchase of expensive equipment and consumables. This is turn is also expected to limit market growth.
Cell Surface Markers Market Report Coverage
||Market Size in 2019:
||US$ 23,037.4 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 44,373.4 Mn
|Geographies covered (27):
- North America: U.S., Canada
- Latin America: Brazil, Argentina, Mexico, Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
- Middle East: GCC Countries, Israel, Rest of Middle East
- Africa: South Africa, North Africa, Central Africa
- By Product Type: Flow Cytometers, Hematology Analyzers, Reagents and Kits
- By Application: Disease Diagnosis & Identification, Research/Drug Discovery
Abbott Laboratories, Inc., Beckman Coulter, Inc., BD Biosciences, Bio-Rad Laboratories, Inc., Grifols SA, Immucor, Inc., Janssen Diagnostics, Inc., Nihon Kohden Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthcare, Sysmex Corporation, and Thermo Fisher Scientific, Inc.
- Growing automation in laboratories
- Increasing product launches
|Restraints & Challenges:
Global Cell Surface Markers Market: Opportunities
Cell surface markers play a vital role in drug discovery and personalized medicine. Thus investment in drug discovery and personalized medicine is expected to offer lucrative growth opportunities for players in the global cell surface markers market. For instance, in May 2020, The Israel Precision Medicine Partnership has chosen 16 multidisciplinary projects that will together receive around US$ 17 million in funding for developing nanoparticles to treat cancer, identifying genes to fight inherited retinal diseases, and studying the genetic aspects of autism.
Moreover, R&D in adoptive immunotherapies is also expected to aid in growth of the market. For instance, in March 2020, researchers from Institute for Tumor Biology and Experimental Therapy, Germany, reported examining expression of various NK-cell-associated cell surface markers in the different feeder cell-expanded NK cell pools in the research ‘Directed Differentiation of Mobilized Hematopoietic Stem and Progenitor Cells into Functional NK Cells with Enhanced Antitumor Activity’.
The global cell surface markers market was valued at US$ 23,037.4 Mn in 2019 and is forecast to reach a value of US$ 44,373.4 Mn by 2027 at a CAGR of 8.6% between 2020 and 2027.
Figure 2. Global Cell Surface Markers Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027
Market Trends/Key Takeaways
Cell surface marker analysis through the use of technologies like flow cytometry is expected to allow simplification of disease analysis, sample preparation and disease diagnosis. Currently a wide range of assay technologies for cell surface marker research are available in the market to enable the analysis of gene expression and regulation, genotyping, signal transduction and epigenetic modification. Some of the most common solutions available for cell surface marker analysis are PCR array, siRNA, miRNA, pathway reporter, mutation analysis, DNA methylation, protein expression and chromatin IP products.
Complexity of high-end flow cytometers and high cost of reagents, controls and analysis systems result in lowering the adoption of sophisticated cell marker analysis solutions, particularly in emerging economies. Increased market consolidation, simplification of analysis products, cost containment of such products and introduction of cheaper products is required to sustain in the cell surface markers market in such regions.
Global Cell Surface Markers Market: Competitive Landscape
Major players operating in the global cell surface markers market include, Abbott Laboratories, Inc., Beckman Coulter, Inc., BD Biosciences, Bio-Rad Laboratories, Inc., Grifols SA, Immucor, Inc., Janssen Diagnostics, Inc., Nihon Kohden Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthcare, Sysmex Corporation, and Thermo Fisher Scientific, Inc.
Global Cell Surface Markers Market: Key Developments
Major players in the market are focused on product approval and launch to expand their product portfolio. For instance, in May 2020, Beckman Coulter launched its DxH 690T hematology analyzer featuring mid-volume laboratories advanced features such as the Early Sepsis Indicator in the U.S.